A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen
• Treatments: Albumin-Bound Paclitaxel; Alkylating Agents; Antibodies, Monoclonal; Antimitotic Agents; Carboplatin; Paclitaxel; Taxane

Criteria

Inclusion Criteria:

• Age >/= 18 years old

• Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer

• ECOG Performance Status 0 or 1

Exclusion Criteria:

• History of another primary cancer within 3 years

• Any prior or concurrent investigational or standard therapy for treatment of NSCLC

• Prior anti-IGF-1R therapy

• Unstable diabetes